Two Medical Marijuana Stocks May Benefit from Federal Rescheduling
The article highlights Trulieve Cannabis and Green Thumb Industries as potential beneficiaries of the U.S. Department of Justice's decision to reclassify cannabis from Schedule I to Schedule III. This change may reduce tax burdens and allow for greater business expansion, particularly in medical marijuana states. The article suggests these stocks could be attractive investment opportunities.
Topics: cannabis medical_marijuana regulatory_changes stock_performance tax_implications